{{Short description|Combination drug}} {{Drugbox | verifiedrevid = 451550479
<!--Combo data--> | type = combo | image = Bupropion and zonisamide.svg | image_class = skin-invert-image | width = 160 | component1 = Bupropion | class1 = Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist | component2 = Zonisamide | class2 = Sulfonamide anticonvulsant
<!--Clinical data--> | tradename = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_status = Investigational | routes_of_administration =
<!--Identifiers--> | CAS_number = 944389-00-8 | ATC_prefix = <!-- 'none' if uncategorised --> | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank =
<!--Chemical data--> }}
'''Bupropion/zonisamide''' (former tentative brand name '''Empatic''', '''Excalia''') is an experimental combination of bupropion which was under development for the treatment of obesity.<ref name="AdisInsight">{{Cite web|url=https://adisinsight.springer.com/drugs/800024638|title=Bupropion/Zonisamide - AdisInsight}}</ref><ref>{{Cite web |url=http://www.medicalnewstoday.com/articles/124468.php |title=Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half |access-date=2010-01-07 |archive-date=2010-01-11 |archive-url=https://web.archive.org/web/20100111014809/http://www.medicalnewstoday.com/articles/124468.php }}</ref><ref>{{Cite web |url=http://www.tesofensine-information.com/empatic.html |title=Empatic Obesity Drug Information and News |access-date=2010-01-07 |archive-date=2017-07-02 |archive-url=https://web.archive.org/web/20170702073330/http://www.tesofensine-information.com/empatic.html }}</ref> Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.<ref name="AdisInsight" /> The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.<ref name="AdisInsight" /><ref>{{cite journal | vauthors = Ioannides-Demos LL, Piccenna L, McNeil JJ | title = Pharmacotherapies for obesity: past, current, and future therapies | journal = Journal of Obesity | volume = 2011 | article-number = 179674 | date = 2011 | pmid = 21197148 | pmc = 3006492 | doi = 10.1155/2011/179674 | url = http://downloads.hindawi.com/journals/jobe/2011/179674.pdf | doi-access = free }}</ref><ref>{{cite journal | vauthors = Adan RA | title = Mechanisms underlying current and future anti-obesity drugs | journal = Trends in Neurosciences | volume = 36 | issue = 2 | pages = 133–40 | date = February 2013 | pmid = 23312373 | doi = 10.1016/j.tins.2012.12.001 | s2cid = 21974224 | doi-access = free }}</ref>
==See also== * Naltrexone/bupropion
==References== {{Reflist}}
{{Ion channel modulators}} {{Monoamine reuptake inhibitors}} {{Nicotinic acetylcholine receptor modulators}}
{{DEFAULTSORT:Bupropion Zonisamide}}
Category:Abandoned drugs Category:Anorectics Category:Anti-obesity drugs Category:Calcium channel blockers Category:Carbonic anhydrase inhibitors Category:Combination anti-obesity drugs Category:Norepinephrine releasing agents Category:Norepinephrine reuptake inhibitors Category:Nicotinic antagonists Category:Sodium channel blockers
{{Nervous-system-drug-stub}}